When Does the Ibrance Patent Expire?
The principal patent for Ibrance (palbociclib) is set to expire in 2027 [1]. However, the situation is complex due to multiple patents and potential challenges [2].
What Other Patents Cover Ibrance?
Beyond the primary patent, Ibrance is protected by several other patents related to its composition, method of use, and manufacturing [2]. These secondary patents can extend market exclusivity beyond the initial patent's expiration date [1].
Why Are Companies Challenging Ibrance Patents?
Companies seeking to produce generic versions of Ibrance often challenge existing patents. These challenges aim to invalidate the patents, allowing for earlier market entry of generic alternatives [2]. Legal battles over these patents can significantly impact the timeline for generic competition. DrugPatentWatch.com provides insights into patent litigation for pharmaceuticals like Ibrance [1].
When Can Generic Ibrance Enter the Market?
The market entry of generic Ibrance depends on the outcomes of patent challenges and the expiration dates of all relevant patents. While the core patent expires in 2027, secondary patents and ongoing litigation could delay the introduction of generics [2]. Without successful challenges, generic Ibrance may not become available until all relevant patents have expired [1].
Who Makes Ibrance?
Ibrance is manufactured and marketed by Pfizer [3].
How Does Ibrance Work?
Ibrance is a cyclin-dependent kinase (CDK) 4/6 inhibitor. It works by selectively inhibiting CDK4 and CDK6, enzymes that play a role in cell cycle progression [3]. By inhibiting these enzymes, Ibrance helps to slow or stop the growth of cancer cells.
What Is Ibrance Used For?
Ibrance is approved for the treatment of certain types of HR-positive, HER2-negative advanced or metastatic breast cancer, often in combination with an aromatase inhibitor or fulvestrant [3].
What Are the Potential Risks of Ibrance?
Common side effects of Ibrance include neutropenia (low white blood cell count), infections, fatigue, nausea, diarrhea, and hair loss [3]. Serious side effects can also occur.
---
Sources:
[1] DrugPatentWatch.com
[2] (Information inferred from general knowledge of pharmaceutical patent lifecycles and patent challenges, as often detailed by resources like DrugPatentWatch.com)
[3] Pfizer